Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis ISTH

NEW HAVEN, Conn. / Apr 03, 2023 / Business Wire / Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract for RLYB212 reporting results from the Phase 1b proof-of-concept study has been accepted for presentation at the 31 Congress of the International Society on Thrombosis and Haemostasis (ISTH), which will take place in Montreal from June 24-28. RLYB212 is an anti-HPA-1a monoclonal antibody being developed for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). Additional information about the ISTH 2023 Congress is available at: https://www.isth2023.org/. About Rallybio Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to…